Apogee says Phase 2 APEX trial shows zumilokibart hits primary endpoint in atopic dermatitis induction study

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

0.00
  • Apogee Therapeutics reported positive 16-week induction results from Part B of its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis.
  • The study met primary and secondary goals, supporting meaningful improvement in skin disease and itch versus placebo without detailing trial metrics.
  • Apogee selected the mid-dose regimen for Phase 3 based on the best overall activity and tolerability across tested doses.
  • Phase 3 trials in atopic dermatitis are planned for the second half of 2026, pending regulatory interactions.
  • The company also outlined expansion plans for zumilokibart, targeting Phase 2 in eosinophilic esophagitis in 2H 2026 and asthma in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270630PRIMZONEFULLFEED9727028) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.